8 completed, 3 active not recruiting, 3 terminated. 7 Phase 1, 4 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Terminated 2 |
| Phase 2 | 4 | Active not recruiting 2, Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Refractory Malignant Neoplasm: new trials by email Literature Review of Refractory Malignant Neoplasm trials Research Report on Refractory Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer Bevacizumab, Fluorouracil, Leucovorin - Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver | Phase 1 | Terminated | M.D. Anderson Cancer Center | 38 | 2020-06-23 | 2026-07-27 |
| Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy Fluorine F 18-fluoroazomycin Arabinoside, Positron Emission Tomography - Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Completed | University of California, San Francisco | 23 | 2020-04-16 | 2023-08-21 | |
| Financial Distress in Advanced Cancer Patients Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration - Advanced Malignant Neoplasm, Locally Advanced Malignant Neoplasm | Active not recruiting | M.D. Anderson Cancer Center | 141 | 2019-07-02 | 2026-10-06 | |
| DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab - Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | Phase 2 | Terminated | M.D. Anderson Cancer Center | 41 | 2018-11-14 | 2024-07-09 |
| Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors Atezolizumab, Cobimetinib - Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 49 | 2017-04-07 | 2025-05-28 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer Antiretroviral Therapy, Biopsy, Biospecimen Collection - AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Completed | National Cancer Institute (NCI) | 58 | 2016-04-04 | 2024-08-09 |
| Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer Dexamethasone, Exercise Intervention, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Fatigue | Phase 2 / Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 90 | 2015-08-13 | 2026-09-22 |
| PCRC-Supported Legacy Intervention in Pediatric Palliative Care Internet-Based Intervention, Best Practice, Quality-of-Life Assessment - Care Giver, Recurrent Malignant Neoplasm | Not applicable | Completed | Vanderbilt-Ingram Cancer Center | 300 | 2015-07-27 | 2023-11-18 |
| Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study - Cirrhosis, Hepatitis B Infection | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2015-01-30 | 2024-11-22 |
| Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - Advanced Malignant Neoplasm, ATM Gene Mutation | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 150 | 2014-12-22 | 2026-06-12 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease | Phase 1 | Terminated | M.D. Anderson Cancer Center | 154 | 2012-10-16 | 2026-05-15 |
| Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers Anakinra, Denosumab, Everolimus - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 57 | 2012-06-19 | 2021-02-25 |
| Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer Everolimus, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 123 | 2012-05-14 | 2026-08-28 |
| Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Neoplasm, BRAF Gene Mutation | Phase 1 | Completed | M.D. Anderson Cancer Center | 46 | 2012-02-06 | 2021-01-22 |
Neoplasms (14) · Neoplasm Metastasis (11) · Recurrence (11) · Carcinoma, Hepatocellular (2) · Adenocarcinoma, Mucinous (1) · Anal Canal Carcinoma (1) · Anus Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Castleman Disease (1) · Endocrine Gland Neoplasms (1) · Erdheim-Chester Disease (1) · Fatigue (1) · Fibrosis (1)
Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Disease Attributes (11) · Neoplastic Processes (11) · Neoplasms by Histologic Type (5) · Carcinoma (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Adenocarcinoma (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3)
Disulfides (3) · Immunoglobulin G (3) · Bevacizumab (2) · Everolimus (2) · Magnetic Resonance Spectroscopy (2) · Sirolimus (2) · Sorafenib (2) · temsirolimus (2) · Antiretroviral Therapy, Highly Active (1) · Biopsy (1) · Calcium Dobesilate (1) · Cetuximab (1) · Crizotinib (1) · Denosumab (1) · Dexamethasone (1)
M.D. Anderson Cancer Center (10) · National Cancer Institute (NCI) (2) · University of California, San Francisco (1) · Vanderbilt-Ingram Cancer Center (1)
United States (14)
Filip Janku (2) · Sarina A Piha-Paul (2) · Brian A Costello (1) · C. Babis Andreadis, MD (1) · Jacqueline Tschanz, MD (1) · Kanwal P Raghav (1) · Kathryn Lurain (1) · Michael M Frumovitz (1) · Sarina Piha-Paul, MD (1) · Siqing Fu (1) · Sriram Yennu (1) · Terrah Akard, PhD (1)
PMID 25982012, PMID 31154457, PMID 31804281, PMID 32996842, PMID 33686901, PMID 33855995, PMID 34965510, PMID 35080914, PMID 37300573, PMID 37311055, PMID 39257031, PMID 39356983, PMID 41389341, PMID 41680482
P30CA016672 (2), P30CA015704 (1), R01NR015353 (1), U01CA154967 (1), UM1CA186686 (1)